Application | Zonisamide is a sulfonamide antiseizure agent approved for use as an adjunctive therapy in adults with partial-onset seizures for adults. It has been shown to block voltage-sensitive T-type Ca2+ and Na+ channels, and stimulate BKCa channels. It has also been shown to modulate glutamate, monoamine, and GABA neurotransmission. It is reported to scavenge nitric oxide and hydroxyl free radicals, and inhibit lipid peroxidation. It exhibits antiParkinsonian and neuroprotective activity. |